244 related articles for article (PubMed ID: 27382363)
1. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines.
Zhang C; Suo J; Katayama H; Wei Y; Garcia-Manero G; Hanash S
Clin Proteomics; 2016; 13():14. PubMed ID: 27382363
[TBL] [Abstract][Full Text] [Related]
2. Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents.
Malkaram SA; Shatnawi A; Fan J; Carraway H; Denvir J; Primerano DA; Abd Elmageed ZY; Fandy TE
Cancer Control; 2022; 29():10732748221074051. PubMed ID: 35067084
[TBL] [Abstract][Full Text] [Related]
3. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
[TBL] [Abstract][Full Text] [Related]
5. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Mao J; Li S; Zhao H; Zhu Y; Hong M; Zhu H; Qian S; Li J
Am J Transl Res; 2018; 10(8):2567-2578. PubMed ID: 30210693
[TBL] [Abstract][Full Text] [Related]
6. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
7. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of post-translational modifications of histone H3 variants during the cell cycle.
Chen J; Hu Y; Yu Y; Zhang L; Yang P; Jin H
Anal Chim Acta; 2019 Nov; 1080():116-126. PubMed ID: 31409460
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
10. Decitabine Enhances Acute Myeloid Leukemia Cell Apoptosis through SH3BGRL Upregulation.
Chen X; Liu F; Rong D; Xu L; Tong X; Wang H
Anticancer Agents Med Chem; 2022; 22(12):2274-2281. PubMed ID: 34963436
[TBL] [Abstract][Full Text] [Related]
11. In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
Wang H; Chen P; Wang J; Santhanam R; Aimiuwu J; Saradhi UV; Liu Z; Schwind S; Mims A; Byrd JC; Grever MR; Villalona-Calero MA; Klisovic R; Walker A; Garzon R; Blum W; Chan KK; Marcucci G
AAPS J; 2013 Jan; 15(1):242-9. PubMed ID: 23180159
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Front Oncol; 2017; 7():19. PubMed ID: 28261562
[TBL] [Abstract][Full Text] [Related]
13. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
16. Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells.
Ma J; Wen X; Xu Z; Xia P; Jin Y; Lin J; Qian J
Cell Cycle; 2023 May; 22(10):1215-1231. PubMed ID: 37032592
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML.
Li H; Wang Y; Feng S; Chang K; Yu X; Yang F; Huang H; Wang Y; Li X; Guan F
Cell Commun Signal; 2023 Sep; 21(1):255. PubMed ID: 37736724
[TBL] [Abstract][Full Text] [Related]
18. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
[TBL] [Abstract][Full Text] [Related]
19. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
